About Agenus
Agenus is a clinical-stage biotechnology company pioneering immunotherapies designed to activate the body’s immune system to fight cancer.
For more than three decades, Agenus has pushed the frontiers of immuno-oncology (IO). Agenus is advancing a comprehensive portfolio of checkpoint inhibitors and immune modulators, combined with cell therapies, designed to expand the reach of immunotherapy—bringing its promise to more patients, more tumor types, and more parts of the world.
At the core of our mission is a belief that immunotherapy should work for everyone. By integrating artificial intelligence, advanced biomarker analytics, and world-class translational science, we’re developing next-generation treatments that harness immune precision to deliver lasting outcomes.
"30 years ago, we envisioned a future where the immune system could be harnessed to cure cancer. That vision remains our driving force today: science-led, patient-focused, and unwavering in our mission to transform outcomes."
Our vision is to broaden the number of patients who benefit from immunotherapy by advancing combination approaches that draw on our diverse portfolio of antibody therapeutics, adoptive cell therapies, and adjuvant and vaccine platforms.
